Currently, Viridian Therapeutics Inc [VRDN] is trading at $22.75, down -2.49%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRDN shares have gain 7.72% over the last week, with a monthly amount glided 51.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on September 11, 2024, when Needham reiterated its Buy rating and also boosted its price target to $38 from $30. Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $29. On June 06, 2024, Goldman initiated with a Buy rating and assigned a price target of $23 on the stock. Ladenburg Thalmann downgraded its rating to a Neutral. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $20 on May 09, 2024. In a note dated June 14, 2023, BTIG Research initiated an Buy rating and provided a target price of $46 on this stock.
This stock has fluctuated between a low of $10.93 and a high of $24.18 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $37.83 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $22.75 at the most recent close of the market. An investor can expect a potential return of 66.29% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Gross Profit Margin for this corporation currently stands at -2.58% with Operating Profit Margin at -870.78%, Pretax Profit Margin comes in at -791.86%, and Net Profit Margin reading is -791.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.5 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.08 points at the first support level, and at 21.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.47, and for the 2nd resistance point, it is at 24.20.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Viridian Therapeutics Inc [NASDAQ:VRDN] is 23.99. As well, the Quick Ratio is 23.99, while the Cash Ratio is 2.93. Considering the valuation of this stock, the price to sales ratio is 5990.31, the price to book ratio is 3.79.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
